



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes
February 16, 2022**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the “Oversight Committee Board Packet” section for the corresponding meeting date.

Call to Order – Agenda Item 1

With a quorum present, Presiding Officer Dr. Mahendra Patel called the meeting to order at 9:00 a.m.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

David Cummings, M.D.
Donald (Dee) Margo
Ambrosio Hernandez, M.D.
Will Montgomery
Mahendra Patel, M.D.
Cindy Barberio Payne
Bill Rice, M.D.
Craig Rosenfeld, M.D.

Adoption of Minutes from the November 18, 2021, Meeting – Agenda Item 3 – Tab 1

MOTION:

On a motion by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the minutes of the November 18, 2021, Oversight Committee meeting as presented.

Public Comment – Agenda Item 4

Presiding Officer Patel noted for the record that no member of the public requested to provide comments.

Chief Executive Officer Report – Agenda Item 5, Tab 2

Presiding Officer Patel recognized Chief Executive Officer Wayne Roberts to present his report.

Mr. Roberts thanked the Higher Education Coordinating Board Commissioner for the use of their facilities. He noted that the new Barbara Jordan State Office building would soon be available for upcoming CPRIT oversight meetings.

Mr. Roberts introduced new staff members Uzoamaka Nwachukwu and Michael Bedford. He recognized the CPRIT IT team for working through management turnover and audit remediation. Dr. Patel joined Mr. Roberts in thanking the IT team on behalf of the Oversight Committee.

Mr. Roberts reported that CPRIT appointed Dr. Kristine Swiderek to serve as CPRIT’s board observer for OncoNano. Dr. Swiderek serves on CPRIT’s Product Development Review Council.

He noted that CPRIT’s 2021 annual report was available online and acknowledged Kristen Doyle, Danielle De La Paz, Mark Loeffler, and Shannon Cusick for spearheading the report.

Mr. Roberts confirmed that there were sufficient funds for the 74 proposed awards and concluded his CEO report with an update on the product development program review that CPRIT staff initiated after the November meeting.

Chief Compliance Officer Report and Compliance Certification for the Proposed Grant Awards – Agenda Item 6, Tab 3

Presiding Officer Patel recognized Chief Compliance Officer Vince Burgess to present the Compliance Report and Compliance Certification of Grant Award Process. Mr. Burgess presented the Compliance Report for the past quarter’s activities. There were no questions for Mr. Burgess.

Following his report, Mr. Burgess certified the award slates that the Oversight Committee will consider today. He noted that he included his written compliance certification report in the Proposed Grant Award packet, beginning at page 97.

Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 7, Tab 4

Presiding Officer Dr. Patel recognized Chief Scientific Officer Dr. Michelle Le Beau to provide the academic research program update and to present the academic research program award recommendations.

Dr. Le Beau directed members to page 6-14 of the Proposed Grants Awards book for the proposed FY22.1 Academic Research Program awards recommended by the Scientific Review Council (SRC) and Program Integration Committee (PIC). She provided an overview of the 59 recommended awards from five grant mechanisms, totaling \$69,581,168.

FY 22.1 Academic Research Award Recommendations

ID	Award Mechanism	Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP220391	IIRA	1.0	Identification of Oncogenic Mechanisms Driving Lung Squamous Cell Carcinoma Development and Progression	Mazur, Pawel	The University of Texas M. D. Anderson Cancer Center	\$997,500
RP220011	IIRAP	1.6	A Randomized, Controlled Trial Comparing the Immunogenicity of 2 doses vs 3 doses of the 9-Valent HPV Vaccine in Females 27 to 45 Years of Age	Berenson, Abbey	The University of Texas Medical Branch at Galveston	\$1,986,984

ID	Award Mechanism	Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP220208	IIRACCA	1.8	Targeting SMARCA4 Mutations in Pediatric Burkitt's Lymphoma	Green, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
RP220312	IIRA	1.8	Interrogating and Targeting Altered Cellular Metabolism in Hürthle Cell Carcinoma of the Thyroid	McFadden, David	The University of Texas Southwestern Medical Center	\$1,049,997
RP220329	IIRA	1.8	ESR1-Mutant Receptor Reliance on the Cell Cycle Checkpoint Sensitizes Tumors to Chk1 and PARP1 Inhibition	Fuqua, Suzanne	Baylor College of Medicine	\$900,000
RP220096	IIRA	1.8	Evolution of Small Cell Lung Cancer from the Normal Airway	Scheet, Paul	The University of Texas M. D. Anderson Cancer Center	\$1,049,739
RP220313	IIRA	1.8	Imaging Metabolic Reprogramming in Prostate Cancer	Pisaneschi, Federica	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
RP220364	IIRA	1.9	KRAS Mutation-Induced KDM5D Upregulation Promotes Male-Specific Colorectal Cancer Metastasis	DePinho, Ronald	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
RP220258	IIRA	1.9	Study AMPK in Ferroptosis Regulation: Mechanisms and Preclinical Translation	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
RP220325	IIRA	1.9	Loss of Site-Specific ADP-Ribosylation of Oncohistones in Cancers	Kraus, W. Lee	The University of Texas Southwestern Medical Center	\$1,027,464
RP220119	IIRAP	1.9	Novel Metabolomics and Radiomics for Predicting HCC Risk	El-Serag, Hashem	Baylor College of Medicine	\$1,995,127
RP220021	IIRAP	1.9	Monitoring of Field Effects for the Detection of Bladder Cancer	Czerniak, Bogdan	The University of Texas M. D. Anderson Cancer Center	\$1,993,172
RP220344	IIRA	1.9	Combination Therapy for Treatment of Sleep Disturbance in Patients with Advanced Cancer	Yennu, Sriram	The University of Texas M. D. Anderson Cancer Center	\$1,048,484
RP220270	IIRA	1.9	Developing Imaging Biomarkers for Immunotherapy Resistance In Vivo	Bhattacharya, Pratip	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
RP220332	IIRA	2.0	Targeting Methylation-Mediated Mitotic Fragility in ccRCC	Dere, Ruhee	Baylor College of Medicine	\$1,049,994
RP220492	IIRA	2.0	Mechanisms of Melanoma Metastasis	Morrison, Sean	The University of Texas Southwestern Medical Center	\$1,045,100
RP220046	IIRA	2.0	Dissect and Disable Altered Tryptophan Metabolism in MYC-Driven Tumors	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$1,049,997

ID	Award Mechanism	Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP220360	IIRACCA	2.0	Epigenetic Regulation of Alternative Lengthening of Telomeres (ALT) in Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,399,992
RP220203	IIRAP	2.0	Brief Computer MI to Motivate Sustained Tobacco Cessation Following Psychiatric Hospital Discharge	Brown, Richard	The University of Texas at Austin	\$1,631,524
RP220366	IIRA	2.0	Automated Image Quality Assessment for AI Applications in Cancer Treatment	Court, Laurence	The University of Texas M. D. Anderson Cancer Center	\$1,037,267
RP220101	IIRA	2.1	Single-Cell Decoding of Spatiotemporal and Ecological Evolution in Early-Stage KRAS-Mutant Lung Cancer	Kadara, Humam	The University of Texas M. D. Anderson Cancer Center	\$1,045,543
RP220532	IIRA	2.1	POSTCare-O: Survivorship Care for Women Living with Ovarian Cancer	Kvale, Elizabeth	The University of Texas at Austin	\$1,016,168
RP220460	IIRACCA	2.1	Telomere Maintenance Mechanisms as Prognostic Biomarkers and Therapeutic Targets in Neuroblastoma and Rhabdomyosarcoma	Reynolds, Charles	Texas Tech University Health Sciences Center	\$1,337,179
RP220150	IIRA	2.1	Turn On Antitumor Immunity in Metastatic Cancers	Gao, Jinming	The University of Texas Southwestern Medical Center	\$1,048,518
RP220242	IIRA	2.2	Tumor Immune Evasion Through Transactivation of STING-Mediated T-Cell Death	Yan, Nan	The University of Texas Southwestern Medical Center	\$1,049,997
RP220410	IIRA	2.2	Mechanisms and Therapies Focused on Epigenomic Alterations in Therapy-Resistant Prostate Cancers	Rai, Kunal	The University of Texas M. D. Anderson Cancer Center	\$1,049,532
RP220235	IIRACCA	2.2	Dual Function of the PRC2 Complex in Medulloblastoma Development	Wu, Jiang	The University of Texas Southwestern Medical Center	\$1,399,996
RP220169	IIRA	2.2	Simultaneous Targeting of LGR4/5/6 for the Treatment of Gastrointestinal Cancer	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$1,050,000
RP220375	IIRA	2.3	Role of Mobile DNA Elements in Leukemia Stem Cells	Xu, Jian	The University of Texas Southwestern Medical Center	\$1,049,997
RP220232	IIRACCA	2.3	Novel Chemical Probes Targeting Critical Protein-Protein Interactions in MLL-Rearranged Leukemia	Song, Yongcheng	Baylor College of Medicine	\$1,400,000
RP220337	IIRA	2.3	Understanding Rewired Intracellular Metabolism in Acute Myeloid Leukemia	Xu, Jian	The University of Texas Southwestern Medical Center	\$1,049,997

ID	Award Mechanism	Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP220299	IIRACT	2.3	The INTERCEPT Trial (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Preemptive Therapy) for Acute Myeloid Leukemia	DiNardo, Courtney	The University of Texas M. D. Anderson Cancer Center	\$1,991,960
RP220309	IIRA	2.4	The Role of Ribosomal RNA Modification in Oncogene-Induced Senescence and Tumorigenesis	Mendell, Joshua	The University of Texas Southwestern Medical Center	\$1,050,000
RP220218	IIRACCA	2.4	Role of Germline BRCA Pathway Mutations in Development of Pediatric Cancers	Plon, Sharon	Baylor College of Medicine	\$1,395,083
RP220041	IIRA	2.4	Strategies for Agitated Delirium in Palliative Care for Patients with Cancer	Hui, David	The University of Texas M. D. Anderson Cancer Center	\$1,020,236
RP220470	IIRA	2.4	Overcoming Liver Toxicity of Anti-CD137 Cancer Immunotherapy	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$969,471
RP220518	IIRA	2.4	Magnetic Nanocluster-Based Heating and Free Radical Generation for Cancer Therapy	Bao, Gang	Rice University	\$1,024,254
RP220267	IIRA	2.5	Organelle Communication During Transition from Fatty Liver to Hepatocellular Carcinoma	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$1,050,000
RP220204	IIRA	2.5	Quantitative NIRFLI Scanning of Lymphatic Dysfunction in Head and Neck Cancer Patients for Early Diagnosis of Cancer-Acquired Lymphedema	Rasmussen, John	The University of Texas Health Science Center at Houston	\$886,095
RP220178	IIRA	2.6	Targeting Isocitrate Dehydrogenase Wild-Type Glioblastoma by a Synthetic Lethal Approach	Luo, Weibo	The University of Texas Southwestern Medical Center	\$1,049,997
RP220032	IIRA	2.7	Targeting Immunosuppressive Myeloid Cells in Tumor Microenvironment	Zhang, Chengcheng	The University of Texas Southwestern Medical Center	\$1,049,997
RP220145	IIRA	2.8	Structures and Targeting of Membrane-Bound RAS Signaling in Cancer	Westover, Kenneth	The University of Texas Southwestern Medical Center	\$1,049,997
RP220473	IIRA	2.8	Overcoming the CPS1-Driven Metabolic Reprogramming and Therapy Resistance in Lethal Prostate Cancer	Mu, Ping	The University of Texas Southwestern Medical Center	\$1,049,997
RP220330	IIRA	2.8	Decoding Bromodomain Chromatin Reader Protein Mechanisms in DNA repair and Replication: Implications for Cancer	Miller, Kyle	The University of Texas at Austin	\$1,050,000
RP220416	IIRA	2.8	Therapeutic Approaches for TGF-Beta-Enriched Minimal Residual Disease in Patients with Colorectal Cancer	Morris, Van	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

ID	Award Mechanism	Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP220524	IIRA	2.9	Development of Next-Generation Estrogen Receptor-Mutant Inhibitors for Endocrine-Resistant Metastatic Breast Cancer	Palaniappan, Murugesan	Baylor College of Medicine	\$769,179
RP220480	IIRA	2.9	RIP PROTACs as a Novel Immunotherapy Sensitizer to Treat Colorectal Cancer	Wang, Jin	Baylor College of Medicine	\$1,050,000
RP220294	IIRACSBC	2.9	Dissecting Intratumor Heterogeneity in Kidney Cancer Using Deep Learning	Rajaram, Satwik	The University of Texas Southwestern Medical Center	\$1,172,136
RP220292	IIRA	3.0	i-SINFOP: Integrative Systems-Scale Interrogation of Neomorphic Fusion OncoProteins	Sahni, Nidhi	The University of Texas M. D. Anderson Cancer Center	*\$900,000
RP220269	IIRA	3.0	MiR223-3p Suppression of BRCA1-Mutant Oncogenesis	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$889,587
RP220468	IIRA	3.0	EIF4A is a New Therapeutic Vulnerability in Triple-Negative Breast Cancer	Rosen, Jeffrey	Baylor College of Medicine	\$949,208
RP220201	IIRA	3.0	Determining the Mechanisms Underlying Sarcomatoid Differentiation in Renal Cell Carcinoma	Carroll, Thomas	The University of Texas Southwestern Medical Center	\$1,040,229
RP220137	IIRAP	3.0	Implementation of Cancer Screening in Children and Adolescents Genetically at High Risk of Cancer	Tomlinson, Gail	The University of Texas Health Science Center at San Antonio	\$1,954,748
RP220127	IIRAP	3.0	Optimizing Population Selection for Primary (Helicobacter pylori Screening) and Secondary (Endoscopic Screening and Surveillance) Prevention of Gastric Cancer	Thrift, Aaron	Baylor College of Medicine	\$1,920,700
RP220225	IIRACSBC	3.0	Imaging-Informed, Biophysical Computational Modeling to Forecast Tumor Progression in Gliomas	Hormuth, David	The University of Texas at Austin	\$1,193,238
RP220244	IIRACCA	3.1	AI-Based Conversational Agent for Facilitating Education and Communication About HPV Vaccination in Children and Adolescents	Tao, Cui	The University of Texas Health Science Center at Houston	\$1,397,258
RP220050	IIRACSBC	3.2	Signaling Network Modeling to Identify New Treatments for Triple-Negative Breast Cancer	Zhang, Bing	Baylor College of Medicine	\$1,200,000
RP220120	IIRA	3.2	Enhancing the Effects of Peptide-Receptor Radionuclide Therapy with a Tumor-Targeted Radiosensitizer	Azhdarinia, Ali	The University of Texas Health Science Center at Houston	\$1,048,533
RP220051	IIRA	3.4	IRE-Based Rational Combination for Effective PDAC Immunotherapy	Li, Chun	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

Dr. Le Beau then directed Oversight Committee members to Table 1 on page 6 of the Proposed Grant Awards Book which displayed the SRC and PIC recommendations for the FY2022 Recruitment Cycles 22.4, 22.5 and 22.6 review cycles, which included six recruitment application totaling \$29,999,382. Dr. Le Beau provided an overview of each recommended application.

FY 2022 Recruitment Cycles 22.4, 22.5, and 22.6 Award Recommendations

Rank	ID	Award Mech.	Overall Score	Application Title	Candidate	Organization	Budget
1	RR220053	REI	1.0	Recruitment of Established Investigators, Reuben Harris	Reuben Harris, Ph.D.	The University of Texas Health Science Center at San Antonio	\$6,000,000
2	RR220054	REI	2.0	Dr Vanderlei Bagnato: Recruitment of Established Investigator	Vanderlei Bagnato, Ph.D	Texas A&M Engineering Experiment Station	\$5,999,721
3	RR220036	RRS	2.0	Recruitment of Rising Star Alison Fout	Alison Fout, Ph.D.	Texas A&M University	\$1,999,661
4	RR220039	RFTFM	2.0	First-Time, Tenure-Track: Dr. Zhi Tan	Zhi Tan, M.D., Ph.D	Baylor College of Medicine	\$2,000,000
5	RR220032	RFTFM	2.3	Recruitment of First-Time, Tenure-Track Faculty Member – Marian Kalocsay	Marian Kalocsay, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
6	RR220038	REI	2.8	Recruitment of Established Investigators - Christopher Chad Quarles	Christopher Chad Quarles, M.D., Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$6,000,000

REI = Recruitment of Established Investigator

RRS = Recruitment of Rising Stars

RFTFM = Recruitment of First-Time, Tenure Track Faculty Members

Conflict of Interest Notification

Presiding Officer Patel noted for the record that Dr. Rosenfeld reported a conflict of interest with one academic research application recommended for an award, grant ID number RP220145.

Approval Process – Academic Research Awards

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Margo the Oversight Committee members voted unanimously to approve the PIC’s recommendation for grant ID number RP220145.

Presiding Officer Patel noted for the record that Dr. Rosenfeld did not vote.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Margo the Oversight Committee members voted unanimously to approve the PIC's recommendations for the following eight grant mechanisms.

- Individual Investigator Research Awards
- Individual Investigator Research Awards for Cancer in Children and Adolescents
- Individual Investigator Research Awards for Computational Systems Biology of Cancer
- Individual Investigator Research Awards for Clinical Translation
- Individual Investigator Research Awards for Prevention and Early Detection
- Recruitment of First-Time, Tenure-Track Faculty Members
- Recruitment of Rising Stars; and
- Recruitment of Established Investigators

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members voted unanimously to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

Chief Prevention Officer Report – Agenda Item 8, Tab 5

Presiding Officer Patel recognized Chief Prevention Officer Ramona Magid to present the proposed prevention awards and to update the Oversight Committee on the prevention program.

Ms. Magid introduced the seven FY 2022.1 prevention program projects, totaling \$13,189,929, that the Prevention Review Council and the PIC recommended for awards. She explained that applicants submitted the proposals in response to two grant mechanisms: *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations* and *Prevention Program Assessment*. Ms. Magid reported that all applications address one or more of the Prevention Program priorities.

An Oversight Committee member asked if grantees could provide all required cancer screenings to one client under one project. Ms. Magid responded that some grantees do provide multiple screenings, but the total grant award funding amount often limits their ability to do so.

Another member asked if the proposed liver cancer project is related to the Academic Research Collaborative Action Program. Ms. Magid stated that she would coordinate this connection.

Ms. Magid clarified the family resident endoscopy training program of proposed project PP220013 in response to a question from an Oversight Committee member.

FY 22.1 Prevention Program Award Recommendations

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP220017	EPS	Leveraging Passport for Care to Reduce Childhood Cancer Survivorship Outcome Disparities in the Rio Grande Valley	Gramatges, Maria M	Baylor College of Medicine	1.9	1	\$983,276
PP220006	EPS	Access to Breast and Cervical Care for West Texas (ABC24WT) – Maintenance and COG-9 Expansion	Layeequr Rahman, Rakhshanda	Texas Tech University Health Sciences Center	2.5	2	\$2,499,999
PP220025	PPA	A Mixed-Methods Evaluation of the CPRIT Prevention Program: Measuring the Reach and Impact of 10 Years of Investment	Chiang, Rachele	Texas Health Institute	2.5	3	\$748,236
PP220005	EPS	Alliance for Colorectal Cancer Testing 3.0 (ACT 3.0)	Foxhall, Lewis E	The University of Texas M. D. Anderson Cancer Center	2.7	4	\$2,500,000
PP220013	EPS	Leveraging Texas C-STEP's Robust Rural Partnerships for Successful Expansion of its Proven Colorectal Cancer Screening Program to Include HCV Screening	McKnight, Jason R	Texas A&M University System Health Science Center	2.7	5	\$2,499,968
PP220015	EPS	Empower Her to Care Expansion (FY2022 - FY2023): Increasing Access to breast Cancer Screening and the Continuum of Care for Underserved Texas Women	Duckworth, Jessica	The Rose	2.9	6	\$1,999,245
PP220022	EPS	Liver Cancer Prevention Among Those with Experiences of Homelessness: An Expansion to Low-Income Housing in South Texas	Schick, Vanessa R	The University of Texas Health Science Center at Houston	3.5	7	\$1,959,205

EPS: Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations

PPA: Prevention Program Assessment

Compliance Certification

Presiding Officer Patel reminded members that Mr. Burgess previously certified compliance of the prevention awards process.

Conflict of Interest Notification

Presiding Officer Patel noted for the record that no Oversight Committee member reported a conflict of interest with any of the proposed prevention awards.

Approval Process - Prevention Grant Awards

Presiding Officer Patel called for a vote on the seven proposed prevention award recommendations.

MOTION:

On a motion made by Dr. Hernandez and seconded by Dr. Cummings, the Oversight Committee unanimously voted to approve the PIC's recommendations for the Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations slate and the Prevention Program Assessment slate.

MOTION:

On a motion made by Dr. Cummings and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the CEO and CPRIT staff and to authorize the CEO to sign the contracts on behalf of CPRIT.

Following the vote on the award recommendations, Ms. Magid provided an update on the status of applications for the second review cycle of FY 2022 and presented three proposed Requests for Applications (RFAs) for FY 2023: *Dissemination of CPRIT-funded Cancer Prevention and Control Interventions, Primary Prevention of Cancer and Screening and Early Detection*.

Presiding Officer Patel requested a motion regarding the proposed FY 2023 RFAs presented by Ms. Magid.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee members unanimously voted to approve the proposed FY 2023 RFAs as presented by Ms. Magid.

Chief Product Development Officer Report – Agenda Item 9, Tab 6

Presiding Officer Patel recognized Chief Product Development Officer Dr. Cindy WalkerPeach to present the proposed product development research award recommendations and to provide the product development research program update.

Dr. WalkerPeach presented the two product development research awards recommended by the Product Development Review Council and the PIC for the FY 2022.1 review cycle totaling \$5,998,261.

FY 2022.1 Product Development Research Award Recommendations

Rank	Application ID	Mechanism	Company Name	Project	Score	Maximum Budget
1	DP220016	SEED	Ares Immunotherapy, Inc.	CD4+CD26high CAR-T Cells for the Treatment of Mesothelioma	2.5	\$2,998,266
2	DP220019	SEED	Iterion Therapeutics, Inc.	Development of a Second-Generation Transducin Beta-like Protein 1 (TBL1) Inhibitor	3.7	\$2,999,995

Dr. WalkerPeach updated the Oversight Committee regarding the status of the applications under review in the second review cycle for FY 2022.

An Oversight Committee member asked about Ares plans to relocate to Texas and whether this was the first Seed grant awarded to a company relocating to Texas. Dr. WalkerPeach confirmed that this was the case.

Compliance Certification

Presiding Officer Patel reminded members that Mr. Burgess previously certified compliance of the product development research awards process.

Conflict of Interest Notification

Presiding Officer Patel noted for the record that no Oversight Committee member reported a conflict of interest with the proposed product development research awards.

Approval Process - Product Development Research Grant Awards

Presiding Officer Patel called for a vote on the two proposed award recommendations.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the PIC's recommendations for product development research awards to Ares Immunotherapy and Iterion Therapeutics.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the CEO and CPRIT staff and to authorize the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Mr. Montgomery and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted pursuant to the General Appropriations Act, Article IX, Section 4.02(a), to authorize CPRIT to disburse grant funds via advance payments to Ares Immunotherapy and Iterion Therapeutics upon execution of the award contracts and the successful completion of tranches.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 11, Tab 8

Presiding Officer Patel recognized Mr. Roberts to present the Scientific Research and Prevention Program Committee appointment.

Mr. Roberts discussed his appointment to the Scientific Research and Prevention Program Committee, also known as the peer review panels.

MOTION:

On a motion by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve Dr. Gene Williams' appointment to the Scientific Research and Prevention Program Committee.

Amendments to 25 T.A.C. Chapters 703 – Item 13, Tab 10

Taking agenda item 13 out of order, Presiding Officer Patel recognized CPRIT assistant general counsel Cameron Eckel to discuss the proposed Final Order and proposed rule change.

Ms. Eckel presented a final order adopting the amendments to T.A.C. § 703.26, which the Oversight Committee initially approved for publication in the *Texas Register* at the November 18, 2021, Oversight Committee meeting.

She also addressed preliminary approval for the proposed amendment to T.A.C. § 703.17, which CPRIT will publish in the *Texas Register* for public comments and bring back to the Oversight Committee for final approval in May.

MOTION:

On a motion made by Dr. Hernandez and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the final order adopting rule changes to the Texas Administrative Code Chapter 703 and to approve the publication of the proposed change to 703 in the *Texas Register*.

Advisory Committees – Item 12, Tab 9

Presiding Officer Patel recognized Mr. Roberts to address the Presiding Officer's new appointment to CPRIT's Prevention Advisory Committee.

Mr. Roberts presented Dr. Manda Hall's appointment to the Prevention Advisory Committee. He noted that the Prevention Subcommittee recommended the appointment.

MOTION:

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee members voted unanimously to approve Dr. Manda Hall's appointment to the Prevention Advisory Committee.

Advisory Committee on Childhood Cancer presentation

Presiding Officer Patel recognized Dr. Le Beau to introduce Dr. Richard Gorlick, Chair of the Advisory Committee on Childhood Cancer (ACCC).

Dr. Le Beau introduced Dr. Gorlick. He presented the ACCC's report.

In response to a question by an Oversight Committee member inquiring if the Pediatric Core Facility resources are available across the state, Dr. Gorlick discussed Dr. Houghton's PDX model as one example of a core facility that researchers across Texas routinely use.

An Oversight Committee member asked Dr. Gorlick if all regions of Texas would benefit from a pediatric clinical trials network. He responded that stated the clinical trials network would be the engine to serve all regions.

University Advisory Committee presentation

Presiding Officer Patel asked Dr. Le Beau to introduce Dr. Peter Davies, Chair of the University Advisory Committee (UAC).

Dr. Le Beau introduced Dr. Davies. He Davies presented the UAC's report.

There were no questions for Dr. Davies.

Prevention Advisory Committee presentation

Presiding Officer Patel asked Ms. Magid to introduce Dr. Navkiran Shokar, Chair of the Prevention Advisory Committee (PAC).

Ms. Magid introduced Dr. Shokar. She presented the PAC report.

There were no questions for Dr. Shokar.

Chief Operating Officer Report – Agenda Item 15, Tab 12

Taking agenda item 15 out of order, Presiding Officer Patel recognized Chief Operating Officer Heidi McConnell for her report.

Ms. McConnell highlighted the second royalty payment received from Merck for approximately \$17,548. She went on to briefly summarize the agency's debt issuance history and answered a question about the interest rates remaining relatively low in the two percent range. In the most recent transaction in which long-term general obligation bonds were issued, the interest rate was 2.19% at the end of November 2021. Lastly, Ms. McConnell informed members that the agency did not receive any bids for the conference venue request for proposal (RFP). The staff was re-evaluating the RFP requirements for the conference, including the date, which CPRIT will delay until 2023 based on proposed venue availability.

The Oversight Committee members discussed with Mr. Roberts and Ms. McConnell the possibility of hosting the CPRIT conference in locations other than Austin.

Communication Report – Agenda Item 17, Tab 13

Presiding Officer Patel recognized Communications Director Mark Loeffler to present his report.

Mr. Loeffler updated the committee members on the communications activities. He highlighted Media Monitoring with daily news updates, implementing Meltwater, and working to increase CPRIT's social media presence.

Internal Auditor Report – Agenda Item 10, Tab 7

Presiding Officer Patel recognized Dan Graves to give the Internal Auditor’s Report.

Mr. Graves updated the committee members on the 2022 Internal Audit Plan schedule. He directed the members to page 7-3 of the meeting book with the list of audits and audit advisory engagements indicating that Weaver would review and re-evaluate the audit follow-ups on information technology general controls, communications, governance, and information security as well as the disaster recovery and business continuity follow-up advisory audit to focus on information technology issues, some of which overlap, around the same time in May-June.

There were no questions for Mr. Graves.

**Texas Publication Act & Open Meeting Act Legislative Update – Agenda Item 14, Tab 11
T.A.C. Section 701.7(d) Training – Agenda Item 16
Consultation with General Counsel – Agenda Item 20**

Presiding Officer Patel called up agenda items 10, 14, 16, and 20 and announced that the Oversight Committee would move into closed session pursuant to Texas Govt. Code Section 551.076 to discuss the internal audit addressing information technology general controls and Texas Govt. Code Section 551.071 to seek advice from counsel regarding agenda items 14, 16, and 20. He asked Mr. Roberts, Ms. Doyle, Ms. McConnell, Shannon Cusick, Mr. Burgess, Ms. Eckel, and Internal Audit team members Mr. Graves and Robert Neill to join the Oversight Committee in closed session.

Presiding Officer Patel convened the closed session at 12:16 p.m. and reconvened the open meeting at 12:50 p.m.

Future Meeting Dates and Agenda Items – Agenda Item 21

Presiding Officer Patel announced that the Oversight Committee would not take up standing agenda items 18 and 19. He noted that the Oversight Committee would convene for its next regular meeting on May 18, 2022.

Adjournment – Agenda Item 24

MOTION:

There being no further business, the Oversight Committee unanimously voted to approve Presiding Officer Patel’s a motion to adjourn, which Mr. Montgomery seconded.

Meeting adjourned at 1:06p.m.

Cindy Barberio Payne
Signature

5/18/2022
Date



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Cynthia Barberis-Lane
Wayne R. Roberts
2/16/22

February 3, 2022

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 74 grant applications totaling \$112,768,740. The PIC recommendations for 65 academic research, 7 prevention, and 2 product development research grant awards are attached.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, Ramona Magid, CPRIT's Chief Prevention Officer, and Dr. Cindy WalkerPeach, CPRIT's Chief Product Development Officer, have prepared overviews of the academic research, prevention, and product development research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on February 16, 2022. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself and Dr. Le Beau, Ms. Magid, and Dr. WalkerPeach are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

RP220270	IIRA	1.9	Developing Imaging Biomarkers for Immunotherapy Resistance In Vivo	Bhattacharya, Pratip	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
RP220332	IIRA	2.0	Targeting Methylation-Mediated Mitotic Fragility in ccRCC	Dere, Ruhee	Baylor College of Medicine	\$1,049,994
RP220492	IIRA	2.0	Mechanisms of Melanoma Metastasis	Morrison, Sean	The University of Texas Southwestern Medical Center	\$1,045,100
RP220046	IIRA	2.0	Dissect and Disable Altered Tryptophan Metabolism in MYC-Driven Tumors	Conacci Sorrell, Maralice	The University of Texas Southwestern Medical Center	\$1,049,997
RP220360	IIRACCA	2.0	Epigenetic Regulation of Alternative Lengthening of Telomeres (ALT) in Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,399,992
RP220203	IIRAP	2.0	Brief Computer MI to Motivate Sustained Tobacco Cessation Following Psychiatric Hospital Discharge	Brown, Richard	The University of Texas at Austin	\$1,631,524
RP220366	IIRA	2.0	Automated Image Quality Assessment for AI Applications in Cancer Treatment	Court, Laurence	The University of Texas M. D. Anderson Cancer Center	\$1,037,267
RP220101	IIRA	2.1	Single-Cell Decoding of Spatiotemporal and Ecological Evolution in Early-Stage KRAS-Mutant Lung Cancer	Kadara, Humam	The University of Texas M. D. Anderson Cancer Center	\$1,045,543
RP220532	IIRA	2.1	POSTCare-O: Survivorship Care for Women Living With Ovarian Cancer	Kvale, Elizabeth	The University of Texas at Austin	\$1,016,168
RP220460	IIRACCA	2.1	Telomere Maintenance Mechanisms as Prognostic Biomarkers and Therapeutic Targets in Neuroblastoma and Rhabdomyosarcoma	Reynolds, Charles	Texas Tech University Health Sciences Center	\$1,337,179
RP220150	IIRA	2.1	Turn On Antitumor Immunity in Metastatic Cancers	Gao, Jinming	The University of Texas Southwestern Medical Center	\$1,048,518
RP220242	IIRA	2.2	Tumor Immune Evasion Through Transactivation of STING-Mediated T-Cell Death	Yan, Nan	The University of Texas Southwestern Medical Center	\$1,049,997
RP220410	IIRA	2.2	Mechanisms and Therapies Focused on Epigenomic Alterations in Therapy-Resistant Prostate Cancers	Rai, Kunal	The University of Texas M. D. Anderson Cancer Center	\$1,049,532
RP220235	IIRACCA	2.2	Dual Function of the PRC2 Complex in Medulloblastoma Development	Wu, Jiang	The University of Texas Southwestern Medical Center	\$1,399,996
RP220169	IIRA	2.2	Simultaneous Targeting of LGR4/5/6 for the Treatment of Gastrointestinal Cancer	Liu, Qingyun	The University of Texas Health Science Center at Houston	\$1,050,000

RP220375	IIRA	2.3	Role of Mobile DNA Elements in Leukemia Stem Cells	Xu, Jian	The University of Texas Southwestern Medical Center	\$1,049,997
RP220232	IIRACCA	2.3	Novel Chemical Probes Targeting Critical Protein-Protein Interactions in MLL-Rearranged Leukemia	Song, Yongcheng	Baylor College of Medicine	\$1,400,000
RP220337	IIRA	2.3	Understanding Rewired Intracellular Metabolism in Acute Myeloid Leukemia	Xu, Jian	The University of Texas Southwestern Medical Center	\$1,049,997
RP220299	IIRACT	2.3	The INTERCEPT Trial (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Preemptive Therapy) for Acute Myeloid Leukemia	DiNardo, Courtney	The University of Texas M. D. Anderson Cancer Center	\$1,991,960
RP220309	IIRA	2.4	The Role of Ribosomal RNA Modification in Oncogene-Induced Senescence and Tumorigenesis	Mendell, Joshua	The University of Texas Southwestern Medical Center	\$1,050,000
RP220218	IIRACCA	2.4	Role of Germline BRCA Pathway Mutations in Development of Pediatric Cancers	Plon, Sharon	Baylor College of Medicine	\$1,395,083
RP220041	IIRA	2.4	Strategies for Agitated Delirium in Palliative Care for Patients With Cancer	Hui, David	The University of Texas M. D. Anderson Cancer Center	\$1,020,236
RP220470	IIRA	2.4	Overcoming Liver Toxicity of Anti-CD137 Cancer Immunotherapy	Tumanov, Alexei	The University of Texas Health Science Center at San Antonio	\$969,471
RP220518	IIRA	2.4	Magnetic Nanocluster-Based Heating and Free Radical Generation for Cancer Therapy	Bao, Gang	Rice University	\$1,024,254
RP220267	IIRA	2.5	Organelle Communication During Transition From Fatty Liver to Hepatocellular Carcinoma	Morita, Masahiro	The University of Texas Health Science Center at San Antonio	\$1,050,000
RP220204	IIRA	2.5	Quantitative NIRFLI Scanning of Lymphatic Dysfunction in Head and Neck Cancer Patients for Early Diagnosis of Cancer-Acquired Lymphedema	Rasmussen, John	The University of Texas Health Science Center at Houston	\$886,095
RP220178	IIRA	2.6	Targeting Isocitrate Dehydrogenase Wild-Type Glioblastoma by a Synthetic Lethal Approach	Luo, Weibo	The University of Texas Southwestern Medical Center	\$1,049,997
RP220032	IIRA	2.7	Targeting Immunosuppressive Myeloid Cells in Tumor Microenvironment	Zhang, Chengcheng	The University of Texas Southwestern Medical Center	\$1,049,997
RP220145	IIRA	2.8	Structures and Targeting of Membrane-Bound RAS Signalingosomes in Cancer	Westover, Kenneth	The University of Texas Southwestern Medical Center	\$1,049,997
RP220473	IIRA	2.8	Overcoming the CPS1-Driven Metabolic Reprogramming and Therapy Resistance in Lethal Prostate Cancer	Mu, Ping	The University of Texas Southwestern Medical Center	\$1,049,997

*CBP
CWI*

RP220330	IIRA	2.8	Decoding Bromodomain Chromatin Reader Protein Mechanisms in DNA repair and Replication: Implications for Cancer	Miller, Kyle	The University of Texas at Austin	\$1,050,000
RP220416	IIRA	2.8	Therapeutic Approaches for TGF-Beta-Enriched Minimal Residual Disease in Patients With Colorectal Cancer	Morris, Van	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
RP220301	IIRA	2.8	Development of Novel Tumor Microenvironment-Targeted Therapy in Inflammatory Breast Cancer	Ueno, Naoto	The University of Texas M. D. Anderson Cancer Center	**\$1,049,839
RP220524	IIRA	2.9	Development of Next-Generation Estrogen Receptor-Mutant Inhibitors for Endocrine-Resistant Metastatic Breast Cancer	Palaniappan, Murugesan	Baylor College of Medicine	\$769,179
RP220480	IIRA	2.9	RIP PROTACs as a Novel Immunotherapy Sensitizer to Treat Colorectal Cancer	Wang, Jin	Baylor College of Medicine	\$1,050,000
RP220294	IIRACSBC	2.9	Dissecting Intratumor Heterogeneity in Kidney Cancer Using Deep Learning	Rajaram, Satwik	The University of Texas Southwestern Medical Center	\$1,172,136
RP220292	IIRA	3.0	i-SINFOP: Integrative Systems-Scale Interrogation of Neomorphic Fusion OncoProteins	Sahni, Nidhi	The University of Texas M. D. Anderson Cancer Center	*\$900,000
RP220269	IIRA	3.0	MiR223-3p Suppression of BRCA1-Mutant Oncogenesis	Hromas, Robert	The University of Texas Health Science Center at San Antonio	\$889,587
RP220468	IIRA	3.0	EIF4A is a New Therapeutic Vulnerability in Triple-Negative Breast Cancer	Rosen, Jeffrey	Baylor College of Medicine	\$949,208
RP220201	IIRA	3.0	Determining the Mechanisms Underlying Sarcomatoid Differentiation in Renal Cell Carcinoma	Carroll, Thomas	The University of Texas Southwestern Medical Center	\$1,040,229
RP220137	IIRAP	3.0	Implementation of Cancer Screening in Children and Adolescents Genetically at High Risk of Cancer	Tomlinson, Gail	The University of Texas Health Science Center at San Antonio	\$1,954,748
RP220127	IIRAP	3.0	Optimizing Population Selection for Primary (Helicobacter pylori Screening) and Secondary (Endoscopic Screening and Surveillance) Prevention of Gastric Cancer	Thrift, Aaron	Baylor College of Medicine	\$1,920,700
RP220225	IIRACSBC	3.0	Imaging-Informed, Biophysical Computational Modeling to Forecast Tumor Progression in Gliomas	Hormuth, David	The University of Texas at Austin	\$1,193,238
RP220244	IIRACCA	3.1	AI-Based Conversational Agent for Facilitating Education and Communication About HPV Vaccination in Children and Adolescents	Tao, Cui	The University of Texas Health Science Center at Houston	\$1,397,258

LUDWIG CANCER RESEARCH

ludwigcancerresearch.org

San Diego

RP220050	IIRACSBC	3.2	Signaling Network Modeling to Identify New Treatments for Triple-Negative Breast Cancer	Zhang, Bing	Baylor College of Medicine	\$1,200,000
RP220120	IIRA	3.2	Enhancing the Effects of Peptide-Receptor Radionuclide Therapy With a Tumor-Targeted Radiosensitizer	Azhdarinia, Ali	The University of Texas Health Science Center at Houston	\$1,048,533
RP220051	IIRA	3.4	IRE-Based Rational Combination for Effective PDAC Immunotherapy	Li, Chun	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)

* This amount reflects the reduction in budget made by the peer review panels and SRC.

** Application withdrawn after SRC recommendation for funding